spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Novasep Announces Major Recapitalisation to Boost its Growth

Novasep

A strongly improved balance sheet, new shareholders and entrepreneurial management to support the group’s development going forward

Novasep, a leading provider of purification-based manufacturing solutions for lifescience molecules, today announces that it has completed its previously-announced process to strengthen its balance sheet and increase its funds available for investment in customer-focused growth initiatives.  
 
Novasep’s approximately EUR 310 million recapitalization includes EUR 30 million of new capital invested by the Fonds Stratégique d'Investissement (FSI), France’s strategic investment fund, which has become a shareholder in Novasep. Azulis, a French investment fund and historical investor of Novasep, also invested EUR three million in equity. As a result, Novasep currently has more than EUR 40 million in cash available for financing growth projects. Moreover, the recapitalization significantly reduces Novasep’s annual interest expense, enabling it to further grow its cash available for investment going forward.
 
In addition to Roger-Marc Nicoud, founder and CEO of Novasep, Novasep’s board also includes Bernard Dubois, former head of Sanofi Aventis’ global industrial operations, Hugues Lecat, CEO and chairman of the management board of the pharmaceutical company Ethypharm, Thomas Devedjan, member of the FSI executive committee, and representatives of the company’s international institutional shareholders.  
 
Roger-Marc Nicoud commented: “I am proud and delighted that we have completed this major transaction and earned the support of the FSI. This is an important endorsement of Novasep's unique business model, which leverages Novasep’s expertise in purification to enable our customers to either insource or outsource to us the production of their active molecules.

"Moreover, these accomplishments have positioned our company for strong growth again now that the refinancing is complete. Novasep can and will now move forward to develop ever more innovative and competitive solutions that will make Novasep an even more valuable partner to our current customers as well as to new customers. I believe this is the best and most important way for Novasep to express our deep appreciation for the continued confidence of our customers, employees and financial stakeholders."
 
Bernard Dubois commented: “I have known Novasep for many years and I am very pleased to contribute to the company’s development and growth, leveraging my experience from the customer perspective.”
 
Thomas Devedjan, member of the FSI executive committee, affirmed: "We are very happy about the recapitalization of Novasep, which significantly strengthens the company's financial structure and, combined with our contribution of EUR 30 million in new capital, will enable the company to pursue its strategy and develop its leading position in purification technologies."

As expected, in addition to the FSI, Novasep shares are now held by a group of international institutional shareholders who have been long-term supporters of the company and holders of company’s securities. The management team has partnered with the new owner group and has received a significant financial stake in the company.
phone +33 3 83 49 71 00
email Novasep@novasep.com
web www.novasep.com
email 81 Boulevard de la Moselle, 54340 Pompey, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Healthera Launches Digital Health Management Platform

Digital health management company announces the launch of its Health Management App
More info >>


White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

Industry Events

PREP_2017

16-19 July 2017,

Advances in Separation Technologies: The PREP series of symposia is the most recognized international conference and exposition devoted to advances in separation technologies in the field of preparative and process chromatography. Join us at PREP 2017 for another dynamic and innovative program where experts from around the world will address the latest developments and hottest topics in all areas of preparative and process chromatography.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement